Novel Inflammatory Markers of Coronary Risk

Novel inflammatory markers of coronary risk: theory versus practice.

For practitioners committed to coronary risk reduction, recent clinical trial data pose a considerable challenge. Specifically, in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), a primary prevention trial,1 treatment with lovastatin among an apparently healthy group of individuals without traditional coronary risk factors resulted in significant reductions in fu...

Clinical depression and inflammatory risk markers for coronary heart disease.

Despite mounting evidence that psychiatric depression heightens risk for cardiac morbidity and mortality, little is known about the mechanisms responsible for this association. The present study examined the relation between depression and the expression of inflammatory risk markers implicated in the pathogenesis of coronary heart disease (CHD). One hundred adults were enrolled (68% women, 48% ...

Novel CT-based imaging markers for high-risk coronary plaques.

A large proportion of patients with suspected coronary artery disease who are referred for coronary computed tomography angiography (CTA) have coronary atherosclerotic lesions that do not cause significant anatomical luminal obstruction. These nonobstructive coronary artery lesions provide incremental prognostic information over the presence of obstructive lesions and clinical variables. 5 Howe...

Novel risk markers and mediators in coronary disease and stroke.

For research and clinical application, the central role of oxidative signalling in cardiovascular pathophysiology –6 positions measures of the redox state conceptually as ideal biomarkers. Despite this overwhelming biological plausibility, no redox biomarker is currently in clinical use, nor have antioxidants provided any clinical benefit in large trials. Recent insights into the mechanistic co...

Inflammatory markers and the risk of recurrent coronary events: the importance of dynamic risk assessment.